Challenges in the Development of Novel Cardiovascular Therapies: New Target for Lowering LDL: PCSK-9 - Cardiology Grand Rounds

Chief Medical Officer of Amgen, Paul Eisenberg, MD, discusses the insights he has learned working on drug development, specifically the cardiovacscular drug that lowers LDL, PCSK-9.

Created by

Medical Professional Education Center


Paul Eisenberg, MD

Paul Eisenberg, MD

Senior Vice President, Global Medical and Chief Medical Officer Amgen